Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias

Background Vincristine sulfate liposome injection (VSLI; Marqibo®) is an encapsulated preparation of standard vincristine in sphingomyelin/cholesterol liposomes. Clinical trials in adults have demonstrated safety, tolerability, and activity, leading to Food and Drug Administration (FDA) approval for...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric blood & cancer Jg. 63; H. 6; S. 997 - 1005
Hauptverfasser:	Shah, Nirali N., Merchant, Melinda S., Cole, Diane E., Jayaprakash, Nalini, Bernstein, Donna, Delbrook, Cindy, Richards, Kelly, Widemann, Brigitte C., Wayne, Alan S.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Blackwell Publishing Ltd 01.06.2016 Wiley Subscription Services, Inc
Schlagworte:	acute lymphoblastic leukemia Adolescent Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - adverse effects Antineoplastic Agents, Phytogenic - pharmacokinetics Chemotherapy Child Child, Preschool Female Hematology Humans Leukemia Liposomes Male Marqibo Maximum Tolerated Dose Neoplasms - drug therapy Oncology pediatric Pediatrics phase I Registries Vincristine - administration & dosage Vincristine - adverse effects Vincristine - pharmacokinetics Young Adult Marqibo phase I acute lymphoblastic leukemia pediatric
ISSN:	1545-5009, 1545-5017, 1545-5017
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!